Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.51 |
| ▸ | GRM5 | P41594 | 9/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275195 | 0.90 | GRM1 (0.49) | PDK4NAMPTCNR1GRM1GRM5 | |
| SCHEMBL7831576 | 0.88 | PDK4 (0.58) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL28675404 | 0.88 | PDK4 (0.55) | PDK4NAMPTCNR1GRM1GRM5 | |
| SCHEMBL29914645 | 0.87 | PDK4 (0.57) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL1364792 | 0.87 | PDK4 (0.57) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL2811392 | 0.87 | PDK4 (0.60) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL652961 | 0.86 | NAMPT (0.60) | PDK4NAMPTCNR1GRM1GRM5 | |
| SCHEMBL2239831 | 0.86 | NAMPT (0.66) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL3988457 | 0.86 | PDK4 (0.56) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL902871 | 0.86 | PDK4 (0.56) | PDK4NAMPTCNR1GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | PDK4 1141/4885NAMPT 1047/4885CNR1 2805/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | PDK4 1141/4885NAMPT 1047/4885CNR1 2805/4885 |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, COASY | PDK4 487/4885NAMPT 532/4885CNR1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.